Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2452)	6/12/2003 11:43:25 AM
From: Tadsamillionaire	Read Replies (1) \| Respond to of 7143

10:28AM Avanir Pharma reports positive Phase II data (AVN) 2.20 +0.29: Results indicated that Neurodex was well tolerated up to the highest target dose, and patients reported decreased pain intensity that was significantly different from baseline. In addition, by Day 8, 91% of the patients reported pain relief compared to baseline, and 97% reported pain relief by Day 15. The degree of pain relief increased with duration of the study. finance.yahoo.com